Revista de Senologia y Patologia Mamaria最新文献

{"title":"Linfedema secundario a cáncer de mama: una revisión narrativa del papel del ejercicio físico","authors":"Ana Belén Puentes Gutiérrez ,&nbsp;Elena Vaquero Ramiro ,&nbsp;María García Bascones","doi":"10.1016/j.senol.2025.100681","DOIUrl":"10.1016/j.senol.2025.100681","url":null,"abstract":"<div><div>The role of exercise in breast cancer-related lymphedema (BCRL) is not clearly defined. The main target of this review is to describe the effects of the different types of exercises on this kind of patient. Bibliographic research was done through the databases of PubMed and PEDro. Controlled trials published between 2017 and 2023 in both Spanish and English, were included. Article selection was carried out separately by 2 researchers using the PICO strategy. Forty-three articles were selected and, after the authors´ review, 19 were included, the majority focused on strength exercises. Strength physical exercise in women with BCRL or at risk of developing it, proved to be safe, even with heavy loads and even during taxanes treatment. Furthermore, it has a beneficial effect on the patients quality of life, in lymphedema symptoms, extremities functionality, and strength gain, although it could not prove its positive role in the prevention or treatment of BCRL. There are no specific protocols for the strength exercise. Other types of exercises such as water sports, pilates, and yoga are considered adequate for these patients.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100681"},"PeriodicalIF":0.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the prospective of gene therapy for the treatment of breast cancer","authors":"Ritika ,&nbsp;Sonam Rani ,&nbsp;Rishabha Malviya ,&nbsp;Shivam Rajput ,&nbsp;Sathvik Belagodu Sridhar ,&nbsp;Dinesh Kaushik","doi":"10.1016/j.senol.2025.100683","DOIUrl":"10.1016/j.senol.2025.100683","url":null,"abstract":"<div><div>Breast cancer (BC) is the most common type of cancer in women and the second most common cause of death from cancer in women around the world. Local therapies, Systematic therapies and advanced systematic therapies are included in current treatment strategies. Gene therapy has become a hopeful way to treat or stop disease by changing bad genes genetically. This innovative strategy aims to replace defective genes, enhance immune defenses, or silence harmful genes. Recent advances in cancer-specific promoter systems make targeted gene treatments possible. These include using suicide genes, cancer suppressor genes, gene silencing technologies, and gene-editing techniques. Among these, CRISPR and CAR-T therapy have revolutionized genetic editing in cancer research, offering high specificity, precision, cost-effectiveness, and efficiency. This review highlights recent advancements in gene therapy targeting cancer-specific promoters, emphasizing its potential to transform BC treatment.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100683"},"PeriodicalIF":0.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiencia inicial en localización mamaria y axilar con semilla ferromagnética en la cirugía del cáncer de mama","authors":"María Jezabel Fernández Carrión ,&nbsp;Laura Jiménez Díaz ,&nbsp;David Ortiz López ,&nbsp;Desireé Armas Ojeda ,&nbsp;Laura Alonso-Lamberti Rizo ,&nbsp;Magali García Suárez ,&nbsp;Manuela Elvira Merola ,&nbsp;Joaquín Marchena Gómez","doi":"10.1016/j.senol.2025.100726","DOIUrl":"10.1016/j.senol.2025.100726","url":null,"abstract":"<div><h3>Introduction</h3><div>Currently, there are localization methods with advantages over the wires. Our objective was to analyze the accuracy and safety of the Magseed® ferromagnetic seed for the localization of non-palpable tumors and axillary lymph nodes in breast cancer patients at our center.</div></div><div><h3>Methods</h3><div>A retrospective observational study from March 2021 to July 2022, which included patients who underwent breast cancer surgery at our institution in whom the Sentimag-Magseed® system (Endomag Ltd.) was used for localization of non-palpable tumors and clip-marked axillary lymph nodes.</div></div><div><h3>Results</h3><div>Magseed® was used in 111 patients, implanted in the breast in 88 (79.3%), in the axilla in 16 (14.4%), and in both breast and axilla in 7 (6.3%). Tumors, marked lymph nodes, and seeds were successfully excised in all cases. In 2 patients (2%), tumor localization required wire (identification rate (IR): 98%). In one case, there was a failure to implant the seed in the tumor (1%). In the axilla, in 2 cases (7%) the seed was in the periganglionic fat. The lymph node IR was 100%. Ten patients (11%) had positive margins. Eight patients (8%) experienced complications unrelated to seed use. There was no operative mortality and no recurrences.</div></div><div><h3>Conclusions</h3><div>The use of the Magseed® seed for the localization of non-palpable tumors and axillary lymph nodes is a safe, reliable, and reproducible method. Studies are needed to assess its long-term results.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100726"},"PeriodicalIF":0.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inteligencia artificial en el diagnóstico por imagen de patología mamaria","authors":"Marina Álvarez-Benito,&nbsp;Esperanza Elías-Cabot,&nbsp;Sara Romero-Martín","doi":"10.1016/j.senol.2025.100684","DOIUrl":"10.1016/j.senol.2025.100684","url":null,"abstract":"<div><div>Artificial Intelligence systems are showing great development in the field of medical imaging. Its role in population screening programs stands out, where these systems can solve many of the problems detected, such as the lack of sensitivity and specificity of mammography, the workload involved in reading a significant number of studies or the introduction of tomosynthesis.</div><div>The ability of AI systems to establish the risk of breast cancer in an agile way undoubtedly represents a very important step towards personalized screening that will allow the selection of technique and frequency for each patient, or the administration of preventive measures and treatments in women at high risk.</div><div>Radiomics analysis of breast cancers from different modalities and in combination with other clinical-pathological data improves tumor characterization, as well as the prediction of prognosis and response to certain therapies.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100684"},"PeriodicalIF":0.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitivity and specificity of MammaTyper® versus immunohistochemistry in the molecular subtyping of breast cancer: The SUBMARIN study","authors":"Laia Bernet-Vegué ,&nbsp;Stella Peláez Malagón ,&nbsp;Marina Berna Rubio","doi":"10.1016/j.senol.2025.100706","DOIUrl":"10.1016/j.senol.2025.100706","url":null,"abstract":"<div><h3>Introduction</h3><div>Immunohistochemical study for oestrogen receptor (ER/<em>ESR1</em>), progesterone receptor (PR/<em>PGR</em>), human epidermal growth factor receptor 2 (HER2/<em>ERBB2</em>), and proliferation marker Ki-67/<em>MKI67</em>PR is the standard technique for diagnosing the molecular subtype in clinical practice. However, less subjective techniques, such as the mRNA-quantifying MammaTyper® (MMT), are needed.</div></div><div><h3>Materials and methods</h3><div>Observational, retrospective, single-centre study carried out at the Vinalopó University Hospital, Alacant, Spain, with 109 consecutive formalin-fixed paraffin-embedded samples coming from infiltrating breast carcinoma diagnosed between 2022 and 2023.</div></div><div><h3>Results</h3><div>The global concordance of MMT with IHC was 76.15%. MMT results were concordant with IHC in all HER2-positive (4, 100%) or HER2-Luminal B samples (11, 100%), in 45 (95.7%) classified as Luminal B-like (HER2–) and in 11 (84.6%) Triple negative. MMT disagreed on 22 (64.7%) Luminal A-like samples, mainly because MMT detected Ki-67 expression. High values of positive agreement for ER (96.3%, 95% CI: 90.9; 98.6%), PR (89.9%, 95% CI: 82.8; 94.3%), and HER2 (87.0%, 95% CI: 67.9; 95.5%) were obtained. MMT detected more positives than IHC for Ki-67 (52.6%, 95% CI: 43.2; 62.0%) and HER2-low (74.3%, 95% CI: 66.1; 82.5%).</div></div><div><h3>Conclusion</h3><div>The concordance between both techniques was high for ER, PR, and HER2. Notably, MMT standardises the identification of Luminal A-B-like and HER2-low thanks to its higher sensitivity towards HER2 and Ki-67.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100706"},"PeriodicalIF":0.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fundamentals of artificial intelligence","authors":"Rafael Guzmán Robles","doi":"10.1016/j.senol.2025.100685","DOIUrl":"10.1016/j.senol.2025.100685","url":null,"abstract":"<div><div>Artificial Intelligence (AI) is revolutionizing various industries, with healthcare being one of the most impacted sectors. This article explores the fundamentals of AI, with a specific focus on machine learning, deep learning, and generative AI. Machine learning, a subset of AI, enables systems to identify patterns in large data sets, improving over time without being explicitly programmed. Deep learning, a more advanced subfield, uses multi-layered neural networks to process complex information. The advent of generative AI, such as GPT and GANs, has expanded the potential of AI to create new content autonomously, transforming areas like drug discovery and personalized medicine. The article also addresses the ethical considerations surrounding the use of AI, particularly concerning data privacy, algorithmic bias, and equitable access to AI-driven technologies. These considerations are essential for ensuring the responsible development and implementation of AI in healthcare.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100685"},"PeriodicalIF":0.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicción de la sobrevida global y libre de recaída en pacientes con cáncer de mama triple negativo a través de agrupaciones basadas en el aprendizaje automático sobre datos clínicos","authors":"Juan Pablo Alzate-Granados,&nbsp;Luis Fernando Niño","doi":"10.1016/j.senol.2025.100686","DOIUrl":"10.1016/j.senol.2025.100686","url":null,"abstract":"<div><h3>Introduction</h3><div>Triple-negative breast cancer (TNBC) accounts for 15%–20% of all breast cancers and is characterised by the absence of hormone and HER2 receptors, limiting therapeutic options to cytotoxic chemotherapy. This subtype is highly aggressive, with frequent relapses and a poor prognosis. The integration of clinical and molecular data using machine learning algorithms offers an opportunity to improve the prediction of clinical outcomes and personalise the management of this disease.</div></div><div><h3>Objective</h3><div>To develop predictive models to estimate overall survival (OS) and relapse-free survival (RFS) in patients with TNBC.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted with 4,808 patients diagnosed between 2012 and 2024. Patients were grouped using the k-prototypes algorithm for mixed data. Demographic and clinical variables, biomarkers, and clinical outcomes were analysed. Multivariate analyses and Cox proportional hazards models were used to assess the association between clusters and OS and RFS outcomes.</div></div><div><h3>Results</h3><div>Four clusters of patients were identified. The highest risk group (cluster 3) had the highest mortality (42.3%; HR: 1.94; 95% CI: 1.63–2.30) and relapse (54.25%; HR: 1.68; 95% CI: 1.45–1.95), whereas cluster 0 had the best outcomes (mortality of 22.51%). Factors such as mutations in PIK3CA (HR: 1.535; <em>p</em> <!-->=<!--> <!-->0.001) and TP53 (HR: 1.180; <em>p</em> <!-->=<!--> <!-->0.023) were associated with adverse outcomes.</div></div><div><h3>Discussion</h3><div>The results support the utility of cluster-based stratification to predict outcomes and guide personalised interventions in TNBC.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100686"},"PeriodicalIF":0.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiosarcoma de mama radioinducido de alto grado: ¿una patología cada vez más incidente?","authors":"Marta Yagüe Medina,&nbsp;Patricia López Arribas,&nbsp;Elena Martínez Gómez","doi":"10.1016/j.senol.2025.100723","DOIUrl":"10.1016/j.senol.2025.100723","url":null,"abstract":"<div><div>Breast angiosarcoma is a very rare neoplasm, accounting for 0.04% of all primary malignant breast tumors. However, in patients who have previously undergone radiotherapy, its incidence increases to 0.16–0.3%. Early diagnosis is challenging due to its wide range of clinical presentations. It is crucial to maintain a high index of suspicion in previously irradiated breasts to enable prompt treatment. Currently, aggressive surgical intervention is the most effective therapeutic approach. Nonetheless, despite surgery, the recurrence rate remains high, contributing to a poor prognosis.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100723"},"PeriodicalIF":0.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145117754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystic neutrophilic granulomatous mastitis associated with Corynebacterium: A systematic review of clinical, pathological, and therapeutic insights","authors":"André R. Guimarães ,&nbsp;Ana Pereira Marques ,&nbsp;António Sarmento","doi":"10.1016/j.senol.2025.100704","DOIUrl":"10.1016/j.senol.2025.100704","url":null,"abstract":"<div><div>Cystic neutrophilic granulomatous mastitis (CNGM) is a rare and underrecognized subtype of granulomatous mastitis, increasingly associated with <em>Corynebacterium</em> species, particularly <em>Corynebacterium kroppenstedtii</em>. Despite a growing number of reports, its diagnosis remains challenging, and treatment approaches are highly variable.</div><div>This systematic review aimed to consolidate the clinical, microbiological, and therapeutic characteristics of CNGM to better inform clinical management. A structured search of PubMed using MeSH terms identified 13 studies, of which 11 met inclusion criteria.</div><div>These studies, encompassing 387 patients, were analyzed for clinical presentation, diagnostic methods, histopathological findings, bacterial species, antimicrobial susceptibility, treatment strategies, and outcomes. CNGM typically presented as a unilateral painful breast mass, frequently accompanied by abscess, nipple inversion, or fistulae. Diagnosis was established via histopathology and confirmed by microbiological testing, often through MALDI-TOFMS or 16S rRNA sequencing. While <em>C. kroppenstedtii</em> was most frequently isolated, recent studies suggest <em>C. parakroppenstedtii</em> may be more prevalent than previously recognized. Antimicrobial susceptibility data revealed consistent resistance to beta-lactams and variable susceptibility to clindamycin and fluoroquinolones, whereas linezolid and vancomycin demonstrated consistent efficacy. Directed antibiotic therapy, particularly with lipophilic agents, combined with abscess drainage, was associated with improved outcomes and lower recurrence. In contrast, higher recurrence rates were reported with corticosteroids or immunosuppressants used in isolation.</div><div>These findings support a multimodal approach as the most effective strategy for CNGM management. Further prospective studies are needed to establish standardized diagnostic criteria and evidence-based treatment guidelines.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100704"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoma pleomórfico indiferenciado de alto grado como tumor primario de mama en una paciente de 12 años: reporte de caso","authors":"Daniela María Cuadrado Franco,&nbsp;Sandra Milena Pantoja Burbano,&nbsp;Natalia Restrepo Abisambra","doi":"10.1016/j.senol.2025.100709","DOIUrl":"10.1016/j.senol.2025.100709","url":null,"abstract":"<div><div>High-grade undifferentiated pleomorphic sarcoma (UPS) of the breast is an extremely rare entity in children, representing less than 1% of malignant breast tumors. It poses a challenge in diagnosis and treatment due to the lack of specific guidelines. We describe the case of a 12-year-old patient with no significant medical history who presented to a tertiary care hospital with a rapidly growing, painful breast mass with cutaneous changes. Imaging studies showed a complex BIRADS 4C mass with no sign of metastasis. The case was submitted to a multidisciplinary board, which indicated primary surgical management. The postoperative pathology report indicated UPS. Adjuvant intensity-modulated radiation therapy (IMRT) and chemotherapy with ifosfamide and doxorubicin were indicated according to the protocol for pediatric non-rhabdomyosarcoma. The patient showed a favorable postoperative outcome, with complete graft healing and no signs of relapse to date. This case highlights the importance of aggressive surgical management and personalized adjuvant treatment in pediatric breast sarcomas, emphasizing the need for additional studies to establish specific management guidelines and optimize outcomes in this population.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100709"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}